Literature DB >> 7508871

Induction of apoptosis in murine ACTH-secreting pituitary adenoma cells by bromocriptine.

D Yin1, S Kondo, J Takeuchi, T Morimura.   

Abstract

Bromocriptine, a dopamine agonist, is now an accepted primary therapeutic agent for patients with prolactinomas and other pituitary adenomas. In this study, we demonstrated that bromocriptine inhibited the proliferation of murine ACTH-secreting pituitary adenoma (AtT-20) cells. In addition, the antitumor activity of bromocriptine was inhibited both by actinomycin D and cycloheximide, suggesting that it was dependent on new RNA and protein synthesis. Interestingly, the results of DNA fragmentation assays and cell cycle analysis clearly demonstrated that bromocriptine induced apoptosis in AtT-20 cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7508871     DOI: 10.1016/0014-5793(94)80387-0

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  20 in total

1.  Apoptosis in Endocrine Glands.

Authors:  George Kontogeorgos; Kalman Kovacs
Journal:  Endocr Pathol       Date:  1995       Impact factor: 3.943

Review 2.  Molecular basis of pharmacological therapy in Cushing's disease.

Authors:  Diego Ferone; Claudia Pivonello; Giovanni Vitale; Maria Chiara Zatelli; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

Review 3.  Pituitary-directed medical therapy in Cushing's disease.

Authors:  Stephan Petersenn; Maria Fleseriu
Journal:  Pituitary       Date:  2015-04       Impact factor: 4.107

Review 4.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

5.  Catecholamines are synthesized by mouse lymphocytes and regulate function of these cells by induction of apoptosis.

Authors:  E Josefsson; J Bergquist; R Ekman; A Tarkowski
Journal:  Immunology       Date:  1996-05       Impact factor: 7.397

6.  Apoptosis in nontumorous and neoplastic human pituitaries: expression of the Bcl-2 family of proteins.

Authors:  E Kulig; L Jin; X Qian; E Horvath; K Kovacs; L Stefaneanu; B W Scheithauer; R V Lloyd
Journal:  Am J Pathol       Date:  1999-03       Impact factor: 4.307

7.  Cabergoline reduces cell viability in non functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion.

Authors:  Teresa Gagliano; Carlo Filieri; Mariella Minoia; Mattia Buratto; Federico Tagliati; Maria Rosaria Ambrosio; Marcello Lapparelli; Matteo Zoli; Giorgio Frank; Ettore degli Uberti; Maria Chiara Zatelli
Journal:  Pituitary       Date:  2013-03       Impact factor: 4.107

8.  Correlation of bcl-2 and bax with apoptosis in human pituitary adenomas.

Authors:  Demetrios Sambaziotis; Nikiforos Kapranos; George Kontogeorgos
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

Review 9.  Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome.

Authors:  C de Bruin; R A Feelders; S W J Lamberts; L J Hofland
Journal:  Rev Endocr Metab Disord       Date:  2008-07-19       Impact factor: 6.514

10.  Effect of cabergoline monotherapy in Cushing's disease: an individual participant data meta-analysis.

Authors:  R Palui; J Sahoo; S Kamalanathan; S S Kar; S Selvarajan; H Durgia
Journal:  J Endocrinol Invest       Date:  2018-08-10       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.